By virtue of their powerful position in the
pharmaceuticals and diagnostics sectors, Taj
Pharmaceuticals is
predestined to develop tailor-made solutions for
diagnostic and therapeutic problems. Against the
background of the first disease management projects
conducted between 1996 and 1998 – in particular in the
field of viral disease (HIV and hepatitis C) –
innovative programmes for different clinical pictures
and fields have been developed to face up to the
challenges of modern medicine today and in the
future.
Taj Pharmaceutical's approach of integrated solutions
aims at developing such combinations of diagnostic and
therapeutic products in close cooperation with the
divisions concerned and bringing them to our
customers.
The incorporation of the new
technological possibilities offered by genome research
can lead in the medium term to treatment that is
customized to the individual needs of each patient.
Integrated solutions such as this will not only benefit
the patient, the will also simplify the situation for
the various healthcare funders.
In order to
develop timely diagnostic and therapeutic solutions of
this nature, the possibilities of future programmes are
evaluated while research is still going on during the
preclinical phase of new therapies.
The aim of
concerted activities is to broaden the range of services
provided by Taj Pharmaceuticals by developing and marketing combined
diagnostic and therapeutic concepts, thus generating
values for our clients and Taj Pharmaceuticals alike. The foundations
for the realisation of this objective rest on three
pillars:
-
Early and improved recognition of patients who may
benefit from Taj Pharmaceutical's substances;
-
Improved and more accurate identification of
patients for the therapies offered;
-
Optimisation and control of therapy by monitoring
treatment results. |
|